Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
JAMA Netw Open. 2021 Nov 1;4(11):e2135362. doi: 10.1001/jamanetworkopen.2021.35362.
Fewer than half of US adults receive the influenza vaccine each year; many cite concerns about side effects, which occur infrequently. By contrast, the recombinant zoster vaccine causes systemic side effects in a large proportion of patients.
To determine whether concurrent administration of the influenza and zoster vaccines was associated with a reduced likelihood of influenza vaccination in the subsequent year.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients aged 50 years or older who received the influenza vaccine between August 1, 2018, and March 31, 2019, and received the zoster vaccine on the same day or separately (within the prior 180 days). Data were gathered from a national claims database of patients with commercial insurance and Medicare Advantage plans. Logistic regression analysis was used to adjust for baseline demographic characteristics, comorbidities, influenza vaccine month and location (pharmacy vs medical office), and health care use (including influenza vaccination in the prior year).
Concurrent vs separate influenza and zoster vaccine administration.
Receipt of the influenza vaccine in the subsequent year (August 1, 2019, to March 31, 2020).
Among 89 237 individuals included in this study, the median age was 72 years (IQR, 67-77 years), 58.3% were women, 70.1% were White, and 85.7% had at least 1 comorbidity. Influenza vaccine uptake in 2019-2020 was lower among 27 161 individuals who received concurrent influenza and zoster vaccines compared with the 62 076 individuals who received the vaccines on separate days (87.3% vs 91.3%; adjusted odds ratio, 0.74; 95% CI, 0.71-0.78; P < .001). Results were similar across subgroups.
Results of this cohort study suggest that concurrent administration of influenza and zoster vaccines was associated with a reduction in receipt of the influenza vaccine the following year. One possible explanation is that some patients could have misattributed systemic side effects caused by the zoster vaccine to the influenza vaccine. It may be preferable to administer these 2 vaccines separately or enhance patient counseling about expected vaccine side effects.
每年,只有不到一半的美国成年人接种流感疫苗;许多人表示担心副作用,但实际上副作用很少发生。相比之下,重组带状疱疹疫苗会导致很大比例的患者出现全身性副作用。
确定同时接种流感疫苗和带状疱疹疫苗是否会降低随后一年接种流感疫苗的可能性。
设计、地点和参与者:本队列研究纳入了 2018 年 8 月 1 日至 2019 年 3 月 31 日期间接种流感疫苗的年龄在 50 岁及以上的患者,以及在同一天或之前 180 天内接种带状疱疹疫苗的患者。数据来自一个全国性的商业保险和医疗保险优势计划患者索赔数据库。采用 logistic 回归分析调整了基线人口统计学特征、合并症、流感疫苗接种月份和地点(药房与医疗办公室)以及医疗保健使用情况(包括前一年的流感疫苗接种情况)。
同时接种或分开接种流感和带状疱疹疫苗。
次年(2019 年 8 月 1 日至 2020 年 3 月 31 日)接种流感疫苗。
在这项研究中,共有 89237 名患者纳入研究,中位年龄为 72 岁(IQR,67-77 岁),58.3%为女性,70.1%为白人,85.7%至少有 1 种合并症。与分开接种两种疫苗的 62076 名患者相比,2019-2020 年同时接种两种疫苗的 27161 名患者中,流感疫苗接种率较低(87.3%比 91.3%;调整后的优势比,0.74;95%CI,0.71-0.78;P<0.001)。各亚组的结果相似。
本队列研究结果表明,同时接种流感疫苗和带状疱疹疫苗与随后一年接种流感疫苗的比例降低有关。一种可能的解释是,一些患者可能将带状疱疹疫苗引起的全身性副作用归因于流感疫苗。最好分开接种这两种疫苗,或加强对患者关于预期疫苗副作用的咨询。